despit
histori
discoveri
trial
evalu
score
differ
compound
current
licens
effect
antivir
common
cold
histori
develop
abandon
potenti
compound
far
teach
us
import
lesson
continu
fight
cold
first
common
cold
benign
selflimit
condit
make
consumpt
harmless
antivir
requisit
prime
import
regul
second
common
cold
syndrom
caus
myriad
known
unknown
agent
reduc
effect
compound
interfer
singl
specif
agent
type
agent
multifactori
natur
genesi
cold
make
difficult
compound
show
vitro
efficaci
make
jump
field
effect
last
despit
heavi
burden
cold
impos
societi
vagu
short
symptom
make
difficult
suffer
present
time
physician
prescrib
antivir
effect
taken
within
short
time
frame
attent
paid
develop
compound
nonvirusspecif
action
despit
ubiquit
natur
high
incid
rel
high
morbid
sever
problem
remain
understand
common
cold
epidemiolog
use
effect
simpl
prevent
therapeut
tool
chapter
focus
antivir
compound
prevent
earli
treatment
common
cold
use
avail
evid
randomis
control
trial
carri
human
volunt
natur
occur
cold
commun
antivir
drug
may
defin
natur
synthet
compound
interfer
differ
stage
cycl
agent
stretch
definit
includ
substanc
act
specif
virus
work
build
immun
respons
chapter
base
earlier
cochran
review
coauthor
late
dr
david
tyrrel
last
director
mrc
common
cold
unit
ccu
origin
dataset
includ
correspond
record
trial
ccu
staff
manufactur
research
activ
field
cochran
review
identifi
trial
antivir
interferon
carri
ccu
year
closur
tab
difficulti
reconcil
raw
data
trial
carri
ccu
publish
intern
journal
time
privileg
raw
record
refer
prefix
ccu
follow
origin
trial
serial
number
eg
ccu
case
lead
investig
name
recognis
exist
record
addit
sever
trial
run
year
make
use
year
identifi
imposs
final
number
trial
ccu
sourc
includ
cochran
review
review
sinc
withdrawn
lack
fund
mainten
hope
vaccin
vitamin
c
antibiot
promethazin
hydrochlorid
grand
total
chapter
serv
memori
huge
amount
work
carri
antivir
common
cold
past
decad
help
direct
work
ahead
ask
updat
content
origin
review
chapter
done
help
trial
search
coordin
alessandro
rivetti
conduct
search
six
differ
databas
today
antivir
regist
common
cold
anywher
world
evid
group
accord
type
compound
rather
commerci
name
compound
present
firstli
pharmaceut
manufactur
known
rout
administr
reader
awar
report
contain
data
sever
substudi
substudi
subdivid
use
alphabet
suffix
discoveri
interest
use
interferon
mark
vitro
antivir
properti
grew
rapidli
earli
method
prepar
interferon
bedevil
problem
impur
lead
high
incid
harm
recipi
avail
earli
puriti
avail
interferon
consider
improv
new
set
trial
could
conduct
knowledg
interferon
grew
sever
type
interferon
synthesis
indic
greek
alphabet
suffix
earli
trial
multipl
arm
two
concern
assess
interferon
control
intervent
tissu
cultur
fluid
potenti
harm
use
earli
experi
volunt
expos
artifici
challeng
mainli
rhinovirus
rv
quarantin
period
rang
day
necessari
minimis
chanc
volunt
expos
virus
circul
commun
isol
period
day
later
interferon
trial
carri
closur
ccu
summer
earliest
trial
report
merigan
advanc
biolog
genet
recombin
interferon
enter
scene
exampl
trial
ccu
report
doubleblind
placebocontrol
studi
selfadminist
intranas
human
interferon
alpha
produc
hoffman
laroch
ltd
schere
plough
ltd
recombin
dna
technolog
administ
viral
challeng
respiratori
coronaviru
four
separ
comparison
construct
avail
data
first
comparison
assess
effect
intranas
interferon
prevent
experiment
cold
caus
varieti
common
cold
viral
type
rhino
corona
parainfluenza
influenza
coxsacki
subtyp
addit
includ
data
differ
commonli
report
advers
event
rang
nasal
stuffi
bloodting
mucu
data
advers
event
comparison
must
read
singli
cumul
one
particip
could
report
one
advers
event
time
result
show
overal
interferon
significantli
efficaci
placebo
prevent
experiment
cold
protect
efficaci
mean
rang
effect
signific
larger
trial
rv
coronaviru
interferon
appear
prevent
middl
ear
eustachian
tube
pressur
dysfunct
although
denomin
small
administr
intranas
interferon
significantli
associ
nasal
stuffi
odd
ratio
increas
sneez
bloodting
nasal
mucu
statist
significantli
associ
exposur
interferon
clear
tendenc
favour
control
intervent
second
comparison
assess
effect
intranas
interferon
prevent
natur
occur
cold
result
show
denomin
consid
number
particip
interferon
overal
significantli
efficaci
placebo
age
group
prevent
natur
occur
cold
prevent
efficaci
caus
rv
prevent
efficaci
despit
neg
outcom
studi
dougla
et
al
reader
note
age
categori
adult
children
famili
mutual
exclus
overlap
year
group
interferon
howev
better
placebo
denomin
consid
number
cours
administ
prevent
efficaci
bloodting
nasal
mucu
observ
statist
signific
increas
frequenc
interferon
arm
trial
natur
occur
common
cold
well
nasal
eros
sneez
nasal
irrit
nasal
stuffi
see
fig
third
comparison
assess
effect
intranas
interferon
combin
synthet
antivir
enviroxim
prevent
experiment
cold
singl
small
trial
higgin
et
al
show
statist
signific
differ
placebo
interferon
eviroxim
efficaci
probabl
reflect
small
denomin
final
fourth
comparison
assess
effect
intranas
interferon
alon
combin
naproxen
ipatropium
treatment
experiment
cold
caus
rv
combin
appear
significantli
effect
placebo
attenu
cours
cold
reduc
amount
nasal
secret
weight
mean
differ
wmd
appear
safe
although
observ
base
singl
studi
interferon
alon
also
significantli
effect
placebo
attenu
cours
experiment
cold
wmd
harm
nasal
discharg
blood
ting
mucu
induc
intranas
administr
interferon
alpha
beta
gamma
prevent
onset
common
cold
commun
age
group
particip
compar
mixtur
donoth
placebo
recipi
forest
plot
meta
analysi
base
observ
interferon
induc
substanc
given
oral
intranas
stimul
natur
intern
endogen
product
interferon
white
cell
six
report
contain
total
ten
randomis
control
trial
effect
interferon
induc
two
comparison
construct
data
first
comparison
interferon
induc
compar
placebo
prevent
experiment
cold
compound
appear
efficaci
placebo
prevent
cold
compound
poli
c
appear
effect
placebo
reduc
sever
ill
wmd
data
difficult
interpret
given
small
denomin
involv
howev
antiplatelet
aggreg
dipyridamol
significantli
effect
placebo
prevent
efficaci
prevent
natur
occur
cold
age
group
one
import
aspect
emerg
data
earli
aerosol
intervent
repeat
continu
intranas
applic
antivir
even
placebo
aerosol
caus
irrit
nose
blockag
case
interferon
substanc
also
induc
system
symptom
mimick
common
cold
combin
side
effect
make
practic
use
earli
intranas
antivir
problemat
although
effect
applic
led
dubiou
benefit
alongsid
assess
interferon
induc
late
earli
saw
growth
attent
capsidbind
compound
interest
although
lower
level
still
aliv
today
name
compound
deriv
biolog
action
base
interfer
viral
capsid
envelop
metabol
replic
time
sever
experiment
compound
investig
use
rv
challeng
pfizer
uk
oral
rhonepoulenc
rp
aerosol
phillip
duphar
du
oral
compound
chemic
structur
similar
amantadin
target
agent
combin
rv
influenza
virus
viral
challeng
studi
show
compound
limit
efficaci
exampl
prevent
efficaci
compound
intranas
spray
rhone
poulenc
rp
synthet
compound
amino
acid
assess
small
trial
inhibit
multipl
rv
cell
cultur
effect
prevent
infect
symptom
challeng
compound
equal
fail
live
vitro
perform
promis
ccu
carri
three
trial
februari
novemb
assess
effect
oral
antivir
b
target
agent
combin
influenza
virus
quarantin
appli
day
isol
day
nasal
spray
oral
eli
lilli
compound
enviroxim
assess
five
trial
carri
target
agent
quarantin
appli
day
isol
day
surviv
ccu
enviroxim
record
appear
contain
data
larger
volunt
popul
correspond
public
rp
prevent
efficaci
enviroxim
prevent
efficaci
rp
prevent
efficaci
cgp
prevent
efficaci
appear
effect
placebo
prevent
experiment
induc
cold
due
rv
influenza
viru
anoth
dead
end
common
cold
antivir
research
experiment
molecul
develop
exist
regist
antivir
oral
compound
ici
cyclononan
compound
relat
amantadin
thought
superior
prevent
therapeut
effect
test
trial
influenza
virus
result
public
surviv
ccu
record
show
good
prevent
efficaci
compar
placebo
prevent
provid
earli
treatment
influenzarel
common
cold
howev
concern
side
effect
mainli
cn
effect
similar
caus
adamantan
amantadin
rimantadin
compound
develop
capsidbind
compound
mix
substanc
case
intranas
spray
janssen
pharmaceut
ltd
pyridazin
mix
cyclodextrin
howev
effect
placebo
prevent
experiment
cold
caus
rv
case
bradykinin
antagonist
nova
pharmaceut
ltd
npc
integr
ccu
data
compound
also
work
alway
intranas
administ
substanc
worsen
clinic
cours
cold
test
oral
eli
lilli
ly
report
trial
carri
usa
compound
appear
effect
placebo
prevent
cold
due
influenza
viru
prevent
efficaci
one
unexpect
find
concern
perform
spofa
pharmaceut
work
oral
impulsin
palmitamid
impulsin
test
three
control
clinic
trial
report
field
trial
carri
male
volunt
czechoslovakian
armi
unit
januari
januari
januari
impulsin
appear
effect
placebo
prevent
acut
respiratori
infect
cold
caus
prevent
efficaci
therapeut
effect
less
mark
pirodavir
spray
janssen
ltd
formerli
known
r
synthet
antivir
phenoxypyridazinamin
potent
vitro
activ
rv
trial
carri
virginia
usa
pirodavir
appear
effect
placebo
prevent
rvinduc
cold
use
least
six
time
day
prevent
efficaci
although
observ
base
small
denomin
individu
therapeut
effect
better
placebo
advers
effect
nasal
dryness
may
affect
complianc
compound
win
sterl
winthrop
inc
oral
effect
placebo
prevent
cold
due
rv
prevent
efficaci
compound
show
antivir
activ
cell
cultur
anim
class
includ
hoffmannla
roch
oral
hydrochlorid
diqa
newport
pharmaceut
oral
inosiplex
isoprinosin
formerli
npt
isoquinolin
deriv
diqa
prevent
efficaci
inosiplex
prevent
efficaci
may
assess
insuffici
denomin
size
latter
appear
promis
prevent
efficaci
data
safeti
profil
compound
avail
hoffmannla
roch
ltd
liquid
chalcon
inactiv
rv
particl
suspens
trial
ccu
ccu
ccu
ccu
assess
prevent
effect
liquid
trial
carri
winter
ccu
ccu
interruptionoftransmiss
trial
volunt
selfinocul
nose
finger
pretreat
either
drug
placebo
ro
chalcon
either
oral
intranas
rout
appear
effect
placebo
prevent
cold
due
rv
conclus
agreement
report
two
publish
version
prevent
efficaci
sever
miscellan
antivir
assess
ccu
group
includ
compound
test
trial
ccu
data
avail
lack
alloc
schedul
lederl
guanidin
liquid
guanidin
cl
test
ccu
trial
trial
carri
usa
lederl
guanidin
appear
effect
placebo
prevent
cold
due
rv
coxsacki
viru
prevent
efficaci
respect
cibageigi
cgp
nasal
liquid
immunomodulatori
compound
shown
antiinfluenza
properti
rodent
ccu
trial
assess
prophylact
effect
cgp
influenza
viru
trial
carri
spring
volunt
complet
psycholog
profil
perform
test
viral
challeng
descript
alloc
method
made
ccu
archiv
identifi
evid
test
miscellan
antivir
compris
follow
compound
aerosol
janssen
ltd
roch
ltd
capsul
ah
oral
ici
evid
thin
compris
either
singl
small
trial
two
three
particip
alloc
code
miss
data
report
compound
final
effect
intranas
nari
nucleosid
analogu
proven
immunomodulatori
activ
coronaviru
test
summer
shortli
closur
ccu
effect
placebo
prevent
cold
due
coronaviru
prevent
efficaci
possibl
reason
failur
confirm
success
rodent
experi
man
includ
inadequ
dosag
differ
concentr
viral
challeng
differ
rodent
human
immun
system
interest
ongo
stori
pleconaril
oral
capsidbind
antivir
develop
jointli
viropharma
inc
sanofisynthelabo
pleconaril
formal
known
win
effect
interfer
capsid
function
picornavirus
especi
rv
vitro
vivo
inhibit
viral
dock
intercellular
adhes
receptor
respiratori
epithelium
particularli
rich
pleconaril
administr
within
hour
symptom
onset
shorten
durat
cold
hour
prevent
role
pleconaril
prevent
rvrelat
cold
despit
notabl
media
hype
promis
phase
ii
trial
result
oral
formul
pleconaril
refus
registr
fda
august
chiefli
basi
side
effect
menstrual
irregular
pregnanc
women
alreadi
oral
contracept
scheringplough
licens
viropharma
complet
phase
ii
clinic
trial
aerosol
formul
pleconaril
common
cold
symptom
asthma
exacerb
result
publish
yet
studi
present
pleconaril
use
compassion
basi
seriou
case
picornaviru
infect
acut
pancreat
howev
effort
develop
effect
antivir
picornavirusassoci
diseas
ongo
rupintrivir
ag
rv
proteas
inhibitor
develop
pfizer
subsidiari
agouron
pharmaceut
reach
clinic
trial
develop
stop
final
antirv
drug
develop
australian
compani
biota
start
phase
ii
prevent
challeng
studi
trial
august
full
result
expect
end
april
effort
direct
interf
viral
function
mediat
antigen
high
level
conserv
across
viral
serotyp
ie
case
rv
serotyp
present
antigen
structur
basi
advanc
understand
viral
dock
uncoat
possibl
design
potenti
antivir
compound
recent
exampl
disubstitut
trisubstitut
benzamid
show
good
vitro
promis
antivir
compound
appear
develop
despit
perus
eight
trial
regist
one
metaregist
trial
publish
report
surviv
record
ccu
allow
systemat
evalu
four
key
design
aspect
antivir
test
human
randomis
schedul
gener
alloc
conceal
blind
complet
followup
howev
possibl
reconstruct
methodolog
look
exist
document
interview
scientist
one
scientist
describ
earli
ccu
viral
challeng
studi
carri
volunt
name
list
also
number
experiment
group
defin
alloc
usual
use
tabl
random
number
yate
group
usual
indic
b
c
written
list
also
use
server
cap
bottl
inoculum
carri
round
flat
list
bottl
could
easili
seen
volunt
clinician
nurs
made
round
separ
see
list
kept
laboratori
drawer
rare
visit
clinic
team
member
scientist
perform
inoculum
often
administ
littl
contact
volunt
earli
trial
might
collect
nasal
secret
cold
develop
influenza
trial
blood
rhinoviru
antibodi
could
often
measur
could
prescreen
volunt
usa
antivir
treatment
stage
might
wast
volunt
could
shown
immun
thu
two
research
would
bleed
volunt
arriv
rapid
antibodi
assay
arrang
volunt
group
similar
antibodi
titr
usual
nil
low
hightitr
individu
might
alloc
experi
altern
viru
placebo
alway
includ
volunt
dummi
inocula
motiv
clinician
volunt
firmli
told
would
given
inert
drop
dummi
drop
would
believ
discourag
report
symptom
fell
placebo
group
ordinarili
group
would
alloc
treatment
random
method
thing
becam
formalis
last
phase
trial
interferon
capsidbind
drug
mani
trial
set
dr
peter
higgin
blind
method
remain
virtual
though
enhanc
distribut
inoculum
trial
volunt
name
label
alloc
inform
never
left
lab
extra
safeguard
volunt
given
wrong
materi
mistak
volunt
accommod
difficult
document
point
precis
date
practic
chang
possibl
work
extent
use
date
clue
suppli
descript
report
paper
generalis
never
open
trial
even
test
effect
hot
humid
air
use
comparison
control
machin
adapt
gener
warm
hot
air
zinc
lozeng
experi
use
strong
wash
flavour
lab
thought
activ
placebo
prepar
tast
direct
comparison
volunt
reorganis
activ
prep
would
want
abl
go
back
experi
contest
challeng
evid
vitamin
c
experi
fault
sort
practic
tell
volunt
end
trial
given
activ
placebo
materi
appear
vitamin
c
reduc
symptom
end
trial
system
includ
volunt
send
back
postcard
report
symptom
got
home
wonder
whether
error
told
volunt
treatment
sent
postcard
report
appar
late
cure
symptom
one
critic
aspect
scientist
decid
defin
cold
evid
diagnosi
cold
within
unit
cours
includ
number
symptom
report
volunt
earli
day
look
object
mean
detect
respons
conclud
best
handkerchief
count
record
increas
five
use
per
day
signifi
cold
nevertheless
number
symptom
could
use
inde
opinion
volunt
cold
seem
reliabl
support
direct
comparison
organis
mrc
epidemiolog
unit
glasgow
order
document
time
cours
measur
respons
quantit
ad
handkerchief
weight
found
nonparametr
statist
could
analys
result
detail
howev
first
year
clear
mildest
cold
could
occur
given
noninfecti
materi
although
summaris
exampl
abort
cold
repres
signific
respons
recognis
excess
nasal
secret
consid
mild
cold
sever
symptom
signifi
moder
cold
system
respons
meant
sever
cold
start
work
influenza
virus
criteria
quit
meet
case
possibl
definit
system
respons
littl
way
respiratori
symptom
trial
ad
separ
assess
system
reaction
gener
think
threshold
signific
cold
similar
virginia
group
australian
small
number
problem
volunt
suscept
ever
present
receiv
critic
fellow
research
two
surviv
ccu
staff
rememb
dealt
problem
volunt
divid
two
group
balanc
age
sex
rapid
antibodi
assay
done
use
serum
collect
arriv
unit
antibodi
assay
result
avail
end
quarantin
period
group
balanc
antibodi
level
also
day
begin
experi
exclud
volunt
notifi
volunt
highest
antibodi
usual
alloc
receiv
salin
placebo
group
alloc
either
drug
placebo
describ
particular
system
method
eg
particular
flat
use
drug
treatment
construct
group
flat
alloc
differ
trial
trial
volunt
questionnair
also
score
psycholog
suscept
usual
turn
alloc
balanc
way
drug
viru
sent
label
volunt
name
drug
trial
volunt
alloc
group
balanc
age
sex
antibodi
titr
viru
given
alway
given
viru
volunt
divid
flat
individu
characterist
particular
method
use
decid
group
treatment
trial
two
differ
virus
run
volunt
high
titr
one
viru
would
put
group
given
one
strict
ensur
volunt
alloc
record
shut
away
laboratori
seen
either
clinic
staff
volunt
would
pass
clinician
final
schedul
volunt
clinic
record
written
sum
outcom
cold
defin
earli
ccu
trial
volunt
present
symptom
coryza
plu
one
constitut
symptom
malais
sore
throat
fever
definit
cold
reli
clinic
score
base
averag
daili
handkerchief
count
presenc
grade
list
sign
symptom
nasal
discharg
nasal
obstruct
postnas
discharg
sinu
pain
red
throat
cervic
aden
hoars
cough
sputum
headach
malais
myalgia
chill
presenc
pyrexia
retir
bed
supplementari
sign
symptom
eg
earach
throughout
review
ccu
data
consid
volunt
present
cold
suffer
mild
moder
sever
cold
defin
ccu
record
mild
doubt
cold
classifi
us
cold
routin
assess
outcom
rise
antibodi
titr
nasal
shed
virus
includ
review
clinic
signific
doubt
would
appear
ccu
trial
standard
method
alloc
particip
mixtur
individu
randomis
cluster
randomis
accommod
block
non
randomis
alloc
depend
compound
test
volunt
number
profil
scientist
involv
read
one
must
rememb
standardis
method
huge
resourc
clinic
registri
avail
time
interferon
effect
prevent
cold
caus
rv
respiratori
syncyti
viru
coronaviru
influenza
virus
eas
applic
counterbalanc
effect
nasal
mucosa
advers
event
due
use
interferon
becam
evid
potent
purer
interferon
becam
avail
revers
infiltr
inflamm
caus
intranas
administr
led
symptom
sign
syndrom
interferon
use
tri
prevent
caus
poor
complianc
ultim
poor
effect
effect
mark
prolong
intranas
administr
littl
said
interferon
effect
treat
ongo
cold
given
small
denomin
relev
studi
difficulti
distinguish
prevent
earli
treatment
observ
confirm
known
effect
interferon
confirm
rational
failur
achiev
develop
registr
best
interferon
induc
appear
dipyridamol
reason
clear
wide
use
cheap
potenti
effect
drug
studi
indic
pleconaril
appear
promis
least
best
test
far
compound
howev
result
trial
aerosol
formul
need
avail
reach
definit
verdict
seen
histori
antivir
develop
litter
promis
compound
fail
live
expect
either
lack
vivo
efficaci
viral
challeng
studi
effect
field
trial
side
effect
prime
import
deal
benign
selflimit
syndrom
like
common
cold
addit
appar
effect
nonspecif
intervent
interferon
dypiridamol
teach
us
import
lesson
deal
effect
purpos
syndrom
caus
score
differ
known
unknown
agent
best
bet
success
lie
introduc
intervent
administ
compound
nonspecif
action
like
erect
physic
barrier
social
distanc
remov
agent
physic
attrit
hand
wash
build
immun
defenc
immunomodul
understand
aetiopathogenesi
common
cold
effort
lie
